Behavioral monitoring and outcome assessment

The manuals converge on repeated outcome monitoring as a core trial activity. Across the extracts, they recommend structured collection of participant-reported data and objective measures, including diaries or logs, questionnaires, and biomarker-based assessment. In both the anxiety and smoking studies, facilitators are expected to review ongoing records for symptoms or side effects, and in the smoking trials they also compare self-report with biological indicators of smoking status. The smoking-focused manuals are especially aligned on using multiple sources to assess abstinence and treatment progress. They mention smoking diary data, timeline follow-back information, exhaled carbon monoxide, urine cotinine, and questionnaires covering self-efficacy, urges, withdrawal, and readiness to quit. One smoking study also specifies seven-day point prevalence abstinence at follow-up, while the later pilot trial emphasises repeated collection across the trial and includes support for remote procedures when visits are virtual. The main difference is in what is being monitored. The anxiety and advanced-stage disease protocol centres on symptoms, quality of life, pain, medication use, and side effects, with daily diary review and scheduled clinical measures such as STAI, EORTC QLQ-C30, HADS, SCL-90-R, SCID, VAPS, and PEP. By contrast, the smoking studies focus on cessation outcomes and smoking-related behaviour, using biomarkers and smoking-specific questionnaires rather than the broader symptom and quality-of-life battery described in the anxiety protocol.